ICVH 2017

GENERAL INFORMATION
The 2017 International Conference on Viral Hepatitis (ICVH 2017) is sponsored by the International Association of Providers of AIDS Care (IAPAC), in partnership with the Alliance to Eliminate HIV/HCV Coinfection (AEH2C) and Rush University Medical Center.

The annual conference is a forum for the presentation of state-of-the-art approaches to the clinical management of viral hepatitis, specifically hepatitis B virus (HBV) and hepatitis C virus (HCV) infection, with the aim of supporting a wide variety of clinicians, including non-liver specialists, as they integrate scientific advances into real-world clinical practice settings.

 

PROGRAM
ICVH 2017 is focused on expanding the universe of clinicians who can manage hepatitis B virus (HBV) and hepatitis C virus (HCV) monoinfection and coinfection with HIV. The conference aims to improve patient outcomes by educating clinicians on practical, state-of-the-science strategies to optimize HBV and HCV treatment in a variety of clinical settings.

The conference Co-Chairs are Nancy Reau, MD (Rush University Medical Center, Chicago, IL, USA) and Vicente Soriano, MD, PhD (Hospital Carlos III, Madrid, SPAIN).

Featured topics on the ICVH 2017 program include:

• HBV and HCV Elimination – The Importance of Modeling
• New HBV Therapeutic Perspectives and Options; Leaving No One Behind
• Casting a Wider Net to Integrate HCV Care into Primary Care
• Myth Busters – Do DAAs Cause HCC? Reactivate HBV?
• Can We Stop “Successful” HBV Treatment? A Debate on the Pros and Cons
• NASH: The New Epidemic in HIV-Coinfected Patients?
• Acute HCV and Its Treatment: Improving Symptoms and Preventing Transmission
• Beyond a Focus on Cure – Dissecting the Current HCV Standard of Care and Liver Complications
• TAF and HBV/HIV Coinfection – Who, When, and How?
• HCV Coinfection – Can We Eliminate HCV without a Focus on MSM?

PRESENTATIONS
Select conference presentations, which will be uploaded daily during the conference, will appear below as the meeting progresses. IAPAC requests that any use of these presentations should include citations to both the presenting authors and relevant conference information (e.g. International Conference on Viral Hepatitis, October 9-10, 2017, Chicago).

MONDAY, October 9, 2017

WELCOME BY CONFERENCE CO-CHAIRS
Nancy Reau, MD
Vicente Soriano, MD, PhD

KEYNOTE ADDRESS: Actioning Sustainable Development Goal 3.3 – Thinking Globally, Acting Locally
Philippa Easterbrook, MD, MPH

PLENARY ADDRESS: HBV and HCV Elimination – The Importance of Modeling
Natasha Martin, DPhil

PLENARY ADDRESS: HDV and HIV Infection – Catalyzing Research around a “Neglected Disease”
Vicente Soriano, MD, PhD

PLENARY ADDRESS: HEV Infection – What Is It? How Do You Find It? Is It Harmful?
Kenneth Sherman, MD, PhD

 

ORAL ABSTRACT SESSIONS
 

<!–

ORAL ABSTRACT SESSION 1: SOF/LDV

25 – Ledipasvir/Sofosbuvir (LDV/SOF) for 8 Weeks in Genotype 1 (GT1) Treatment-Naïve (TN) Non-Cirrhotic (NC) Patients with HCV Viral load (VL) <6 million IU/ml (6M): A Comparative Analysis of the Phase-3 ION-3 Efficacy Data to Real World Effectiveness (RWE)

Norah Terrault presenting

15 – Ledipasvir/Sofosbuvir is Safe and Effective for the Treatment of Patients with Genotype 1 Chronic HCV Infection in Both HCV Mono- and HCV/HIV-Coinfected Patients

Anne Luetkemeyer presenting

22 – A Single Tablet Regimen of Ledipasvir &plus; Sofosbuvir is Efficacious and Well-Tolerated among People Receiving Opiate Substitution Therapy

Nancy Reau presenting
 

ORAL ABSTRACT SESSION 2: HCV Treatment Challenges

8 – Comorbidities and Co-Medications of Patients with Chronic Hepatitis C (CHC) under Specialist Care in the UK – Challenges for Scaling up HCV Treatment?

Ben Hudson presenting

42 – Bringing Hepatitis C Treatment into the Medical Home

Joanna Eveland presenting

36 – Real-World Effectiveness of Direct-Acting Antivirals for Hepatitis C among HIV-infected Patients with Genotype 1

Edward Cachay presenting
 

ORAL ABSTRACT SESSION 3: SOF/VPV (ASTRALs)

26 – A Phase 3 Double-Blind Placebo-Controlled Evaluation of Sofosbuvir/Velpatasvir Fixed-Dose Combination for 12 Weeks in Treatment-Naïve and -Experienced Genotype 1, 2, 4, 5, 6 HCV-Infected Patients with and without Cirrhosis: Results of the ASTRAL-1 Study

Anne Luetkemeyer presenting

27 – Sofosbuvir/Velpatasvir for the Treatment of HCV in Patients with Decompensated Liver Disease: The ASTRAL-4 Study

Norah Terrault presenting

33 – Sofosbuvir/Velpatasvir for 12 wks vs Sofosbuvir+Ribavirin for 24 Weeks in GT 3 HCV Patients: The Phase 3 ASTRAL-3 Study

Nancy Reau presenting
 

–>

PLENARY ADDRESS: Changes in HCV Screening to Identify People Missed by Birth Cohort
John Ward, MD

PLENARY ADDRESS: HCV Mechanisms of Sexual Transmission – What Do We Know?
Daniel S. Fierer, MD

CASE STUDIES: Acute HCV Treatment – Improving Symptoms, Preventing Transmission
Moderator: Mark Nelson, MD • Presentation
Panelist 1: Donald M. Jensen, MD
Panelist 2: Kenneth Sherman, MD, PhD

PLENARY ADDRESS: New HBV Therapeutic Perspectives and Options
Robert Perrillo, MD

PLENARY ADDRESS: HBV Reactivation – Who, When, and How?
Fred Poordad, MD

POSTER SESSION

TUESDAY, October 10, 2017

Panel Discussion: Beyond a Focus on Cure – Dissecting the Current HCV Standard of Care
Moderator: Nancy Reau, MD • Presentation
Panelist 1: Wendy Spearman, MBChB, MMEd, PhD • Presentation
Panelist 2: Mark Nelson, MD

Panel Discussion: Resistance to DAAs – Do We Need More HCV Treatment Options and/or Resistance Testing?
Moderator: David Wyles, MD
Panelist 1: Andrew Aronsohn, MD
Panelist 2: Massimo Puoti, MD • Presentation

PLENARY ADDRESS: Myth Busters – Do DAAs Cause HCC? Reactivate HBV?
Massimo Puoti, MD

Debate Session: Does HCV Therapy with DAAs Prevent or Simply Delay Liver Transplants?
Moderator: Vicente Soriano, MD, PhD
Debater 1: Michael Charlton, MBBS
Debater 2: Helen S. Te, MD • Presentation

PLENARY ADDRESS: Project ECHO – Lessons Learned, Opportunities Seized, Challenges Overcome
Sanjeev Arora, MD

PANEL DISCUSSION: Leaving No One Behind – Casting a Wider Net to Integrate HCV Care into Primary Care
Moderator: Wendy Spearman, MBChB, MMEd, PhD
Panelist 1: Stacy Trooskin, MD • Presentation
Panelist 2: Philippa Easterbrook, MD, MPH

PLENARY ADDRESS: NASH – The New Epidemic in HIV-Coinfected Patients?
Edward Cachay, MD

PLENARY ADDRESS: TAF and HBV/HIV Coinfection – Who, When, and How?
Kosh Agarwal, MD

Panel Discussion: HCV Coinfection in HIV-Positive MSM – Can We Eliminate HCV without a Focus on this Key Population?
Moderator: David Wyles, MD
Panelist 1: Daniel S. Fierer, MD
Panelist 2: Vicente Soriano, MD, PhD

2017 Conference Program and Abstracts
Click below to download the complete 2017 Program and Abstracts book in PDF format.

Requires free Acrobat Reader Plugin Software